An interventional study of riboflavin and UVX Light in Infectious Keratitis, sponsored by Price Vision Group. Terminated at 1 site in United States. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2017-11-22.
Sponsored by Price Vision Group · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Corneal Ulcer with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Corneal Ulcer · United States.
Among the 22 studies in Corneal Ulcer with a site in United States, this one is the 15th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2009, is one of 3 with no phase, and was the 5th registered.
63 studies on the registry are indexed under Corneal Ulcer; 8 are open to participants now.
Browse Corneal Ulcer studies →4 of the 22 studies in Corneal Ulcer with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States, India
Ages 18+
Jeremy Keenan, MD, MPH · Sites in United States, Brazil, India and 1 more country
Ages 8+
University of Illinois Chicago · Sites in United States
Ages 18+
Vishal Jhanji · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Corneal Ulcer studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 14 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 8 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 60 across 45 interventional studies indexed under Corneal Ulcer.
Median enrollment 150 across the 19 interventional studies, 55 across the 3 observational. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 22 have an industry lead sponsor. The 10 most frequent:
Price Vision Group is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Price Vision Group has 1 study filed under Corneal Ulcer — fewer than ten, so there is no comparison to draw.
2 of the studies in Corneal Ulcer with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06658002Phase 3University of California, San FranciscoFungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A | 2027-09-01 |
| NCT05705024University of Illinois ChicagoEfficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells | 2026-12-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Corneal Ulcer with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is comparing 45 minute and 30 minute treatment durations with the UVX corneal cross linking system to treat corneal infections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 minute treatment with UVX light
Drug: riboflavin · Device: UVX Light
45 minute treatment with UVX light
Device: UVX Light
riboflavin 0.1% is applied every 2 minutes for 30 minutes
UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
Time to Re-epithelialization
Time frame: Day 1, day 2, day 3, day 4, day 5, day 6, day 7, week 2, and subsequent weekly assessments until re-epithelialization is complete
Time to Resolution of Stromal Infiltration
Time frame: day 1, day 2, day 3, day 4, day 5, day 6, day 7, week 2, and subsequent weekly assessments until infiltrate is completely resolved
| Milestone | 30 Minute Light Duration | 45 Minute Light Duration |
|---|---|---|
| Started | 20 | 10 |
| Completed | 15 | 7 |
| Not completed | 5 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Lack of efficacy | 4 | 3 |
| Days | 30 Minute Light Duration | 45 Minute Light Duration |
|---|---|---|
| Time to Re-epithelialization | 14 (6 to 28) | 11 (6 to 29) |
| days | 30 Minute Light Duration | 45 Minute Light Duration |
|---|---|---|
| Time to Resolution of Stromal Infiltration | 21 (8 to 33) | 10 (7 to 11) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 30 Minute Light Duration | — | 0/20 (0%) | 5/20 (25%) |
| 45 Minute Light Duration | — | 0/10 (0%) | 4/10 (40%) |
| Event | 30 Minute Light Duration | 45 Minute Light Duration |
|---|---|---|
| Cornea transplantEye disorders | 4/20 | 2/10 |
| Intracorneal injection of voriconazoleEye disorders | 1/20 | 1/10 |
| Dendritic lesions characteristic of prior herpes simplexEye disorders | 0/20 | 1/10 |
This is the number of participants who were culture-positive
| Age, Categorical(Participants) | 30 Minute Light Duration | 45 Minute Light Duration | Total |
|---|---|---|---|
| <=18 years | 1 | 0 | 1 |
| Between 18 and 65 years | 13 | 4 | 17 |
| >=65 years | 6 | 6 | 12 |
| Sex: Female, Male(Participants) | 30 Minute Light Duration | 45 Minute Light Duration | Total |
|---|---|---|---|
| Female | 14 | 6 | 20 |
| Male | 6 | 4 | 10 |
The record gives a start of May 2009, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Riboflavin
Price Vision Group